BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, March 8, 2026
Home » Blogs » BioWorld MedTech Perspectives » Jim Mazzo: A case of loose lips or a deliberate slip?

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

Medical technology

Jim Mazzo: A case of loose lips or a deliberate slip?

Sep. 13, 2012
By Mark McCarty

There isn’t much that stays behind closed doors these days, and the case of Jim Mazzo, the outgoing CEO of Advanced Medical Optics, might be nothing more than a case of camaraderie-loosened lips … or something more toxic.

To recap, Mazzo, has been charged by the SEC with insider trading violations thanks to trades made by several former professional baseball players. The thread of the story seems to be that Mazzo told Doug DeCinces in 2008 of the then-impending move by Abbott to acquire AMO. It appears DeCinces then relayed the scoop to a couple of other former major league baseball players, who along with DeCinces bought shares in AMO ahead of the acquisition and walked away with a considerable payday for their very meager efforts.

One of the reports said that Mazzo and DeCinces met for dinner Oct. 22, 2008, and that Mazzo e-mailed DeCinces the following day “and suggested they talk.” The obvious question is, what did they talk about?

That is the question one assumes will be answered by the SEC investigation, but it’s tough to draw any conclusions just yet. One explanation is that Mazzo talked about his job regularly with DeCinces. They were neighbors, after all. Did Mazzo trust DeCinces not to say or do something stupid? Another explanation is that Mazzo knew DeCinces would use the information, but didn’t expect DeCinces to blab to his cronies.

Frankly, I find it tough to believe Mazzo would be dumb enough to run his boca if he thought DeCinces was going to do anything. After all, Wall Street got a warning shot when Martha Stewart did time in connection with shares of ImClone in 2004, just four years earlier. Did anyone in the Western hemisphere not get the flyer?

My guess is Mazzo will be hit with a fine even in the most innocuous of circumstances. Mazzo may then want to hit DeCinces with a left hook, assuming Mazzo thought he was just talking to a friend about a day on the job. Should the SEC divulge the contents of the e-mail, we may find it said something incredibly incriminating, or something such as “we really need to talk Doug. I’m getting some very strange phone calls!” If Mazzo settles out of court, we’ll never know. Ditto if the  SEC drops the charges, but that would tell us pretty much everything we need to know, anyway, a statement that might apply to an out-of-court settlement as well.

I know I sound like an apologist for corporate America to some people, but I just have a hard time believing Mazzo is dumb enough to knowingly leak information he figured someone would act on. Mazzo’s reputation will be sullied in any event, though, which just goes to show that loose lips can still sink all kinds of ships.

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for March 6, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for March 3, 2026
  • Tanycytes in green capturing tau protein in red.

    Brain’s hidden tau-clearing pathway uncovered

    BioWorld Science
    Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
  • Microscopic image of clear cell carcinoma, the most common type of renal cell carcinoma.

    Cas and effect: Merck’s phase III ripples HIF-2α space

    BioWorld
    Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
  • Muscarinic M4 receptor positive allosteric modulators described in Neurosterix patent

    BioWorld Science
    Neurosterix Pharma Sarl has divulged 3-cyclopropylpyrazole derivatives acting as muscarinic M4 receptor positive allosteric modulators. They are reported to be...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing